Reardon Andrew: insider trades.
Reardon Andrew reported 26 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 23 sales ($4.4M), across 1 company.
- Transactions
- 26
- Purchases (P)
- 0
- Sales (S)
- 23
- Companies
- 1
- Name as filed
- Reardon Andrew
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Ligand Pharmaceuticals Inc (LGND) | Officer · CLO & Secretary | 26 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-03 | Ligand Pharmaceuticals Inc | S | 385 | $287.53 | 36,914 | Form 4 |
| 2026-09-03 | Ligand Pharmaceuticals Inc | S | 1,800 | $285.17 | 39,414 | Form 4 |
| 2026-09-03 | Ligand Pharmaceuticals Inc | S | 2,115 | $286.36 | 37,299 | Form 4 |
| 2026-09-03 | Ligand Pharmaceuticals Inc | S | 300 | $283.99 | 41,214 | Form 4 |
| 2026-09-03 | Ligand Pharmaceuticals Inc | S | 400 | $288.98 | 36,514 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 200 | $290.6 | 42,914 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 991 | $291.71 | 41,923 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 409 | $292.82 | 41,514 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | M | 5,000 | $52.27 | 46,514 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 105 | $284.14 | 46,409 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 33 | $284.55 | 46,376 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 157 | $285.74 | 46,219 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 1,032 | $286.8 | 45,187 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 1,214 | $287.77 | 43,973 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 356 | $288.75 | 43,617 | Form 4 |
| 2026-08-03 | Ligand Pharmaceuticals Inc | S | 503 | $289.8 | 43,114 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 600 | $317.15 | 41,514 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 900 | $315.78 | 42,114 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 100 | $314.58 | 43,014 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 700 | $313.46 | 43,114 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 1,081 | $312.28 | 43,814 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 1,119 | $311.72 | 44,895 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 104 | $310.2 | 46,014 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | S | 396 | $308.99 | 46,118 | Form 4 |
| 2026-07-01 | Ligand Pharmaceuticals Inc | M | 5,000 | $52.27 | 46,514 | Form 4 |
| 2026-06-30 | Ligand Pharmaceuticals Inc | J | 132 | $160.71 | 41,514 | Form 4 |
Questions
What stock did Reardon Andrew buy or sell?
Reardon Andrew reported 26 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 23 sales ($4.4M), across 1 company.
Is Reardon Andrew the same person as other filers with this name?
This page covers SEC CIK 1950232 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/reardon-andrew-1950232.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.